Adonis vs Moderna

Side-by-side comparison of AI visibility scores, market position, and capabilities

Moderna leads in AI visibility (90 vs 34)
Adonis logo

Adonis

EmergingDigital Health

Healthcare Revenue Cycle AI

Raised $40M Series C (Mar 2026) led by Quadrille Capital and General Catalyst. $95M+ total. 4x revenue growth 2025. 130%+ NRR. Clients: Mount Sinai, Baptist Health, AdventHealth.

AI VisibilityBeta
Overall Score
D34
Category Rank
#576 of 596
AI Consensus
80%
Trend
stable
Per Platform
ChatGPT
37
Perplexity
29
Gemini
36

About

Adonis is an AI-powered healthcare revenue cycle management (RCM) platform targeting the surging hospital denial crisis: payer denials are now the primary driver of healthcare revenue risk, with denial rates increasing year-over-year as commercial payers deploy more aggressive prior authorization and claims review protocols. The company raised $40 million in Series C financing in March 2026 led by Quadrille Capital and General Catalyst, bringing total funding to $95 million+ on the back of 4x revenue growth in 2025.

Full profile
Moderna logo

Moderna

LeaderHealthcare Tech

Enterprise

mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.

AI VisibilityBeta
Overall Score
A90
Category Rank
#2 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
92
Perplexity
93
Gemini
89

About

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.

Full profile

AI Visibility Head-to-Head

34
Overall Score
90
#576
Category Rank
#2
80
AI Consensus
83
stable
Trend
stable
37
ChatGPT
92
29
Perplexity
93
36
Gemini
89
36
Claude
96
34
Grok
95

Key Details

Category
Healthcare Revenue Cycle AI
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Adonis
Healthcare Revenue Cycle AI

Integrations

Only Moderna
Moderna is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.